Researchers found that nearly 15% of commercially insured PrEP users had an alcohol use disorder diagnosis, yet fewer than 9% received FDA-approved treatment.
The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.
Researchers found that breast-conserving treatment provided long-term survival outcomes comparable to mastectomy in patients with breast cancer and BRCA1 or BRCA2 pathogenic variants.